NEW YORK, NY / ACCESSWIRE / November 27, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortress Biotech, Inc. (“Fortress Biotech” or “the Company”) (NASDAQ:FBIO). Investors who purchased Fortress Biotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/fbio.
The investigation concerns whether Fortress Biotech and certain of its officers and/or directors have violated federal securities laws.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) IV Tramadol was not safe for the intended patient population; (2) as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you are aware of any facts relating to this investigation, or purchased Fortress Biotech shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/fbio. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com: